We are live on ! Find out more
NVNO

enVVeno Medical

36 hedge funds and large institutions have $5.4M invested in enVVeno Medical in 2025 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

850% more call options, than puts

Call options by funds: $114K | Put options by funds: $12K

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

1.96% more ownership

Funds ownership: 29.04%30.99% (+2%)

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

3% less funds holding

Funds holding: 3736 (-1)

73% less capital invested

Capital invested by funds: $20.3M → $5.4M (-$14.9M)

Holders
36
Holders Change
-1
Holders Change %
-2.7%
% of All Funds
0.47%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
12
Reduced
5
Closed
12
Calls
$114K
Puts
$12K
Net Calls
+$102K
Net Calls Change
-$977K

NVNO Hedge Fund Activity: Q3 2025 in Review

36 of the 7,643 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q3 2025, worth a combined $5.4M — down 73% from $20.3M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of NVNO and 11 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 12 added.

The largest buyer was CM Management, opening a new position worth an estimated $1.75M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $2.37M sold.

  • 36 institutional investors held enVVeno Medical (NVNO) as of Q3 2025, down from 37 in Q2 2025.
  • Funds reported $5.4M of enVVeno Medical stock for Q3 2025, down 73% quarter-over-quarter.
  • 11 funds opened new enVVeno Medical positions in Q3 2025 and 12 closed out, a net change of -1 holder.
  • The largest enVVeno Medical buyer in Q3 2025 was CM Management, an estimated $1.75M added.
  • The largest enVVeno Medical seller in Q3 2025 was Nantahala Capital Management, an estimated $2.37M sold.

Based on aggregated 13F filings for Q3 2025.